Production (Stage)
Silence Therapeutics plc
SLN
$5.19
$0.193.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 142.00K | 25.55M | 1.49M | 754.40K | 15.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 142.00K | 25.55M | 1.49M | 754.40K | 15.70M |
| Cost of Revenue | 54.00K | 2.26M | 3.61M | 3.33M | 2.80M |
| Gross Profit | 88.00K | 23.28M | -2.12M | -2.57M | 12.90M |
| SG&A Expenses | 7.68M | 6.78M | 7.29M | 6.67M | 6.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.87M | 18.77M | 30.81M | 23.87M | 18.79M |
| Operating Income | -25.73M | 6.77M | -29.33M | -23.11M | -3.09M |
| Income Before Tax | -28.53M | 19.34M | -39.25M | -22.00M | -2.07M |
| Income Tax Expenses | -- | 9.00M | -4.09M | -2.37M | 244.00K |
| Earnings from Continuing Operations | -28.53M | 10.34M | -35.15M | -19.63M | -2.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.53M | 10.34M | -35.15M | -19.63M | -2.31M |
| EBIT | -25.73M | 6.77M | -29.33M | -23.11M | -3.09M |
| EBITDA | -25.59M | 6.92M | -29.18M | -22.96M | -2.93M |
| EPS Basic | -1.81 | 0.66 | -2.24 | -1.26 | -0.16 |
| Normalized Basic EPS | -0.38 | 0.26 | -0.52 | -0.29 | -0.03 |
| EPS Diluted | -1.81 | 0.66 | -2.24 | -1.26 | -0.16 |
| Normalized Diluted EPS | -0.38 | 0.26 | -0.52 | -0.29 | -0.03 |
| Average Basic Shares Outstanding | 47.23M | 47.23M | 47.07M | 46.74M | 43.96M |
| Average Diluted Shares Outstanding | 15.74M | 15.74M | 15.69M | 15.58M | 14.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |